MX381305B - Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis. - Google Patents

Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis.

Info

Publication number: MX381305B
Authority: MX; Mexico
Prior art keywords: sub; atp; syndrome; methods; prader
Prior art date: 2014-11-14

Application number

MX2017006244A

Other languages

English (en)

Spanish (es)

Other versions

MX2017006244A (es

Inventor

Neil M Cowen

Original Assignee

Essentialis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-14

Filing date

2015-11-12

Publication date

2025-03-12

2015-11-12 Application filed by Essentialis Inc filed Critical Essentialis Inc

2018-02-26 Publication of MX2017006244A publication Critical patent/MX2017006244A/es

2025-03-12 Publication of MX381305B publication Critical patent/MX381305B/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Steroid Compounds (AREA)

MX2017006244A 2014-11-14 2015-11-12 Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis. MX381305B (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201462080150P	2014-11-14	2014-11-14
US201562138245P	2015-03-25	2015-03-25
US201562170035P	2015-06-02	2015-06-02
US201562221359P	2015-09-21	2015-09-21
PCT/US2015/060455 WO2016077629A1 (en)	2014-11-14	2015-11-12	Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Publications (2)

Publication Number	Publication Date
MX2017006244A MX2017006244A (es)	2018-02-26
MX381305B true MX381305B (es)	2025-03-12

Family

ID=55955075

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MX2021003982A MX393030B (es)	2014-11-14	2015-11-12	Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms)
MX2017006244A MX381305B (es)	2014-11-14	2015-11-12	Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MX2021003982A MX393030B (es)	2014-11-14	2015-11-12	Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms)

Country Status (19)

Country	Link
US (8)	US10058557B2 (2)
EP (1)	EP3217963B1 (2)
JP (4)	JP6709226B2 (2)
KR (4)	KR102598666B1 (2)
CN (3)	CN113599386B (2)
AU (2)	AU2015346196B2 (2)
BR (1)	BR112017009986A2 (2)
CA (4)	CA3125839C (2)
DK (1)	DK3217963T3 (2)
EA (1)	EA036103B1 (2)
ES (1)	ES2806977T3 (2)
HU (1)	HUE050895T2 (2)
IL (1)	IL252111B (2)
MX (2)	MX393030B (2)
MY (1)	MY187610A (2)
NZ (1)	NZ768958A (2)
PL (1)	PL3217963T3 (2)
SG (1)	SG11201703721SA (2)
WO (1)	WO2016077629A1 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2342090T3 (es)	2004-08-25	2010-07-01	Essentialis, Inc.	Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos.
US9757384B2 (en)	2005-04-06	2017-09-12	Essentialis, Inc.	Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CN101868239B (zh)	2006-01-05	2015-06-10	伊森舍丽斯有限公司	钾atp通道开放剂的盐及其用途
PL3217963T3 (pl)	2014-11-14	2020-10-19	Essentialis, Inc.	Sposoby leczenia osobników z zespołem pradera-williego lub smith-magenis
IL263412B (en)	2016-06-03	2022-08-01	Univ Columbia	Treatment methods for Freder Willi syndrome
US11382881B2 (en)	2017-05-05	2022-07-12	Nino Sorgente	Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en)	2017-05-05	2018-11-08	Nino Sorgente	Methods and compositions for improving eye health
KR20210062638A (ko) *	2018-09-20	2021-05-31	레보 테라퓨틱스 인코포레이티드	카르베토신의 안정한 비강내 제형
CN111888330B (zh) *	2020-09-18	2022-08-16	常州市第四制药厂有限公司	一种二氮嗪口服混悬溶液及制备方法
TW202430507A (zh) *	2022-10-18	2024-08-01	美商律森製藥股份有限公司	新穎atp-敏感性鉀通道增效劑、其製備及用途
AU2024341097A1 (en) *	2023-09-15	2026-04-23	Soleno Therapeutics, Inc.	Methods of managing glycemic control in prader-willi syndrome patients
WO2025222188A1 (en) *	2024-04-18	2025-10-23	Rhythm Pharmaceuticals, Inc.	Novel potassium channel opener compounds and related uses

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2986573A (en)	1961-01-18	1961-05-30	Schering Corp	Method for the treatment of hypertension
GB8601204D0 (en)	1986-01-18	1986-02-19	Boots Co Plc	Therapeutic agents
GB2186485B (en)	1986-02-13	1988-09-07	Ethical Pharma Ltd	Slow release formulation
US5284845A (en)	1991-03-14	1994-02-08	Paulsen Elsa P	Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5629045A (en)	1992-09-17	1997-05-13	Richard L. Veech	Biodegradable nosiogenic agents for control of non-vertebrate pests
US5399359A (en)	1994-03-04	1995-03-21	Edward Mendell Co., Inc.	Controlled release oxybutynin formulations
FR2725623A1 (fr)	1994-10-18	1996-04-19	Flamel Tech Sa	Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6225310B1 (en) *	1996-01-17	2001-05-01	Novo Nordisk A/S	Fused 1,2,4-thiadiazine derivatives, their preparation and use
AU4133997A (en)	1996-09-12	1998-04-02	Yarom Cohen	Pharmaceutical composition for the treatment of syndrome x of reaven
US6197765B1 (en)	1999-06-08	2001-03-06	Pnina Vardi	Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
AU2001265840A1 (en)	2000-06-26	2002-01-08	Novo-Nordisk A/S	Use of potassium channel agonists for reducing fat food comsumption
TW478039B (en)	2001-04-09	2002-03-01	Promos Technologies Inc	Phase shift alignment system
US6669955B2 (en)	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6960346B2 (en)	2002-05-09	2005-11-01	University Of Tennessee Research Foundation	Vehicles for delivery of biologically active substances
WO2004043534A1 (en)	2002-11-12	2004-05-27	Collegium Pharmaceutical, Inc.	Inertial drug delivery system
US20040204472A1 (en)	2003-03-04	2004-10-14	Pharmacia Corporation	Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
EP1782812A1 (en)	2004-06-23	2007-05-09	Neurotec Pharma, S.L.	Compounds for the treatment of inflammation of the central nervous system
CN101043879A (zh) *	2004-08-25	2007-09-26	伊森舍丽斯有限公司	钾atp通道开放剂的药物制剂及其应用
ES2342090T3 (es)	2004-08-25	2010-07-01	Essentialis, Inc.	Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos.
JP2008517976A (ja) *	2004-10-25	2008-05-29	ゾルファイファーマスーティカルズゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
US9757384B2 (en)	2005-04-06	2017-09-12	Essentialis, Inc.	Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CN101257897A (zh) *	2005-07-07	2008-09-03	西特里斯药业公司	用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
CN101868239B (zh)	2006-01-05	2015-06-10	伊森舍丽斯有限公司	钾atp通道开放剂的盐及其用途
CA2655144A1 (en) *	2006-06-15	2007-12-21	Gilead Colorado, Inc.	Antihypertensive therapy method
CN101795691A (zh)	2007-07-02	2010-08-04	伊森舍丽斯有限公司	钾atp通道开放剂的盐及其用途
US20120238554A1 (en)	2007-07-02	2012-09-20	Cowen Neil M	Salts of potassium atp channel openers and uses thereof
US20120053172A1 (en) *	2009-02-12	2012-03-01	Cooperatieve Mirzorg U.A.	Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
PL2790721T3 (pl) *	2011-12-15	2019-05-31	Millendo Therapeutics Sas	Fragmenty nieacylowanej greliny do zastosowania do leczenia zespołu pradera-williego
WO2013130411A1 (en)	2012-02-27	2013-09-06	Essentialis, Inc.	Salts of potassium atp channel openers and uses thereof
JP2014074004A (ja) *	2012-10-05	2014-04-24	Shinichi Niijima	精神症状の改善剤
US20140364367A1 (en)	2013-06-08	2014-12-11	Sedogen, Llc	Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
PL3217963T3 (pl)	2014-11-14	2020-10-19	Essentialis, Inc.	Sposoby leczenia osobników z zespołem pradera-williego lub smith-magenis

2015
- 2015-11-12 PL PL15859169T patent/PL3217963T3/pl unknown
- 2015-11-12 NZ NZ768958A patent/NZ768958A/en unknown
- 2015-11-12 KR KR1020237010935A patent/KR102598666B1/ko active Active
- 2015-11-12 CA CA3125839A patent/CA3125839C/en active Active
- 2015-11-12 SG SG11201703721SA patent/SG11201703721SA/en unknown
- 2015-11-12 CA CA2966907A patent/CA2966907C/en active Active
- 2015-11-12 ES ES15859169T patent/ES2806977T3/es active Active
- 2015-11-12 JP JP2017544842A patent/JP6709226B2/ja active Active
- 2015-11-12 CA CA3125835A patent/CA3125835C/en active Active
- 2015-11-12 MX MX2021003982A patent/MX393030B/es unknown
- 2015-11-12 KR KR1020177016089A patent/KR102323613B1/ko active Active
- 2015-11-12 CN CN202110786768.6A patent/CN113599386B/zh active Active
- 2015-11-12 KR KR1020227029800A patent/KR102517840B1/ko active Active
- 2015-11-12 CN CN202511504739.0A patent/CN121910740A/zh active Pending
- 2015-11-12 KR KR1020217035884A patent/KR102452254B1/ko active Active
- 2015-11-12 AU AU2015346196A patent/AU2015346196B2/en active Active
- 2015-11-12 CN CN201580072525.9A patent/CN107106500B/zh active Active
- 2015-11-12 DK DK15859169.3T patent/DK3217963T3/da active
- 2015-11-12 HU HUE15859169A patent/HUE050895T2/hu unknown
- 2015-11-12 CA CA3210794A patent/CA3210794A1/en active Pending
- 2015-11-12 MY MYPI2017701659A patent/MY187610A/en unknown
- 2015-11-12 BR BR112017009986-1A patent/BR112017009986A2/pt not_active Application Discontinuation
- 2015-11-12 EP EP15859169.3A patent/EP3217963B1/en active Active
- 2015-11-12 EA EA201791067A patent/EA036103B1/ru unknown
- 2015-11-12 WO PCT/US2015/060455 patent/WO2016077629A1/en not_active Ceased
- 2015-11-12 MX MX2017006244A patent/MX381305B/es unknown
2017
- 2017-05-04 IL IL252111A patent/IL252111B/en unknown
- 2017-08-08 US US15/671,792 patent/US10058557B2/en active Active
2018
- 2018-07-20 US US16/041,237 patent/US10456408B2/en active Active
2019
- 2019-04-25 AU AU2019202906A patent/AU2019202906B2/en active Active
- 2019-09-17 US US16/573,965 patent/US10874676B2/en active Active
2020
- 2020-01-10 JP JP2020002555A patent/JP6955039B2/ja active Active
- 2020-11-25 US US17/104,433 patent/US20210322434A1/en not_active Abandoned
2021
- 2021-09-30 JP JP2021160423A patent/JP7232300B2/ja active Active
2023
- 2023-02-17 JP JP2023023047A patent/JP7645913B2/ja active Active
2024
- 2024-01-24 US US18/421,914 patent/US12109216B2/en active Active
- 2024-09-04 US US18/824,811 patent/US12178823B1/en active Active
- 2024-12-19 US US18/988,636 patent/US12343348B2/en active Active
2025
- 2025-05-30 US US19/224,580 patent/US12419895B1/en active Active

Also Published As

Publication number	Publication date
CA3125835A1 (en)	2016-05-19
US20250120979A1 (en)	2025-04-17
JP6709226B2 (ja)	2020-06-10
US20180021344A1 (en)	2018-01-25
US20250288593A1 (en)	2025-09-18
US10874676B2 (en)	2020-12-29
EA036103B1 (ru)	2020-09-29
CA2966907C (en)	2021-09-07
EP3217963A4 (en)	2018-07-04
NZ731565A (en)	2021-06-25
SG11201703721SA (en)	2017-06-29
KR20170082625A (ko)	2017-07-14
US20200147100A1 (en)	2020-05-14
US12419895B1 (en)	2025-09-23
IL252111A0 (en)	2017-07-31
CN113599386A (zh)	2021-11-05
US20190105327A1 (en)	2019-04-11
JP6955039B2 (ja)	2021-10-27
EP3217963A1 (en)	2017-09-20
JP2021193148A (ja)	2021-12-23
MX2017006244A (es)	2018-02-26
US10456408B2 (en)	2019-10-29
CA3125839A1 (en)	2016-05-19
US20240423996A1 (en)	2024-12-26
CA2966907A1 (en)	2016-05-19
WO2016077629A1 (en)	2016-05-19
BR112017009986A2 (pt)	2018-02-14
JP2020073566A (ja)	2020-05-14
KR20230049760A (ko)	2023-04-13
DK3217963T3 (da)	2020-07-20
NZ768958A (en)	2021-07-30
CN107106500A (zh)	2017-08-29
KR102323613B1 (ko)	2021-11-09
KR102598666B1 (ko)	2023-11-07
AU2015346196A1 (en)	2017-06-29
MX2021003982A (es)	2022-06-09
MY187610A (en)	2021-10-04
CA3125835C (en)	2023-01-03
CN113599386B (zh)	2025-12-05
KR20220124289A (ko)	2022-09-13
US20240207284A1 (en)	2024-06-27
KR102452254B1 (ko)	2022-10-11
CA3125839C (en)	2023-10-24
AU2019202906B2 (en)	2020-05-21
EA201791067A1 (ru)	2017-11-30
PL3217963T3 (pl)	2020-10-19
KR102517840B1 (ko)	2023-04-05
HUE050895T2 (hu)	2021-01-28
AU2019202906A1 (en)	2019-05-16
JP2017533972A (ja)	2017-11-16
CA3210794A1 (en)	2016-05-19
US20210322434A1 (en)	2021-10-21
US12178823B1 (en)	2024-12-31
US10058557B2 (en)	2018-08-28
MX393030B (es)	2025-03-24
CN107106500B (zh)	2021-07-30
ES2806977T3 (es)	2021-02-19
IL252111B (en)	2021-09-30
EP3217963B1 (en)	2020-05-20
KR20210134843A (ko)	2021-11-10
US12109216B2 (en)	2024-10-08
CN121910740A (zh)	2026-04-24
AU2015346196B2 (en)	2019-01-31
US12343348B2 (en)	2025-07-01
JP2023056025A (ja)	2023-04-18
JP7232300B2 (ja)	2023-03-02
HK1243954A1 (en)	2018-07-27
JP7645913B2 (ja)	2025-03-14

Publication	Publication Date	Title
MX381305B (es)	2025-03-12	Métodos para tratar sujetos con el sindrome de prader-willi o el síndrome de smith-magenis.
DK1968601T3 (da)	2012-02-06	Salte af kalium-ATP-kanalåbnere og anvendelser heraf
DK1781265T3 (da)	2010-08-02	Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
MX2020008977A (es)	2020-09-28	Formulaciones de anticuerpos de her2 subcutaneas.
CL2019001265A1 (es)	2019-10-04	Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
MX392606B (es)	2025-03-24	Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
MX2019003173A (es)	2019-07-08	Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MY188139A (en)	2021-11-23	Sodium channel modulators for the treatment of pain
MX377576B (es)	2025-03-04	Formulaciones de pridopidina de liberación modificada.
MX2020010194A (es)	2020-10-20	Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
AR086051A1 (es)	2013-11-13	Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit
MY174727A (en)	2020-05-11	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX386251B (es)	2025-03-18	Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
MX376200B (es)	2025-03-07	Formulacion en polvo nasal para el tratamiento de hipoglicemia.
CO2017003263A2 (es)	2017-07-28	Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
UY36202A (es)	2016-01-29	Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
PH12016502233A1 (en)	2017-02-06	(s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016016400A (es)	2017-06-12	Formulaciones de oximetazolina estabilizadas y sus usos.
MA39743A (fr)	2017-01-18	Fumarate de diméthyle et régimes de vaccination
MY205748A (en)	2024-11-11	Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
TW201642854A (en)	2016-12-16	Fixed dose combination for pain relief without edema
MX391734B (es)	2025-03-21	COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE IgG PARA EL TRATAMIENTO DE UNA INMUNODEFICIENCIA.
AR130700A2 (es)	2025-01-08	Composiciones de grapiprant y métodos para su utilización
HK1142824A (en)	2010-12-17	Salts of potassium atp channel openers and uses thereof
Cosme	2016	Amoxicillin/clarithromycin/metronidazole/omeprazole